9th Annual MarketsandMarkets

Biomarker and Companion Diagnostics Conference - West Coast Edition

8th - 9th February 2024

Double Tree by Hilton, San Diego - Mission Valley

Leveraging next gen technologies beyond conventional biomarker drug discovery!

MarketsandMarkets bring to you the 9th Annual Biomarker and CDx Conference - West Coast Edition scheduled to be held on 8th - 9th February 2024 in San Diego, USA. This event will have an introduction to turning biomarkers into companion diagnostics.

30+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Biomarkers and Personalized Medicine, Impact of Big data in translational biomarker research and Future of Companion Diagnostics
Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.
Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials.

The Expert Panel will take you through their presentations which will include problems, solutions and services in the Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases. Attendees would evidence the examples and the case studies which will help in creating the revenue. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

CO-LOCATED CONFERENCES

WHAT TO EXPECT

  • Commercialization of CDx
  • Proteomics and Genomics based Biomarkers
  • Biomarker Drug Discovery and Assay Development
  • Multiplex Companion Diagnostics and Regulatory Guidelines
  • Design of clinical trials in CDx
  • Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
  • Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

  • Biomarker discovery/development
  • Translational research
  • Clinical Biomarker
  • Biomarkers in IO and Neurological disorders
  • Imaging Biomarkers
  • Pathology
  • Companion Diagnostics
  • Biomarker Imaging
  • Proteomics Biomarkers
  • Experimental Medicine
  • Data Science
  • Biomarkers in Clinical Discovery
  • Immuno-oncology/Neuroscience Drug Discovery
  • Diagnostic Biomarkers development
  • Personalized Medicine
  • Immunology Biomarkers

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION

Keynote Presentation

09:00 - 09:30

Spatial Analysis in Ulcerative Colitis and Crohn’s Disease

Jiangwei Zhang

Jiangwei Zhang, Senior Principal Scientist, Bristol Myers Squibb

09:30 - 10:00

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Development of Methylation and Mutation Panel for Colorectal Cancer

Collin

Collin, Scientist, EpigenDx

11:15 - 11:45

Opportunities for biomarker development in neuroscience

Pablo Lapuerta

Pablo Lapuerta, Chief Executive Officer, 4M Therapeutics Inc.

11:45 - 12:15

The crucial role of biospecimen management in precision medicine

Ayat Alsaraby

Ayat Alsaraby, Sr. Manager, Clinical Biomarker, Repare Therapeutics

12:15 - 12:45

AI and Multimoodal Biomarkers for Personalized Pain Medicine

Carl Saab

Carl Saab, Professor, Innovation Lead Digital Health, Cleveland Clinic

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

ROLE OF BIOMARKERS IN PERSONALIZED MEDICINE

Solution Provider Presentation

14:15 - 14:45

Identifying Variants Associated with Creatinine and Cystatin C Serum Levels in the Top 1% of the Population Provides Insight into the Genetic Architecture of Kidney Function and Chronic Kidney Disease

Matteo D’Antonio

Matteo D’Antonio, Assistant Professor, University of California, San Diego

14:45 - 15:15

Why is monitoring predictive biomarker data so difficult for big pharma?

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Patient Identification and Stratification applying predictive models

16:30 - 17:00

Use of Real-World Evidence in discovery of digital biomarkers

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 17:35

Drinks Reception & Networking

17:35 - 17:35

End of Day 1

17:35 - 17:35

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairman

08:55 - 09:00

FROM BIOMARKERS TO CDX: STRATEGIES TO ACCELERATE CDX DEVELOPMENT AND COMMERCIALIZATION

Keynote Presentation

09:00 - 09:30

Strategies to optimize CDx in cancer

09:30 - 10:00

Solution Provider Presentation

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Drug and CDx co-development with a therapeutic product

11:15 - 11:45

Solution Provider Presentation

11:45 - 12:15

CDx Launch Success: From Early Biomarker Development to Commercialization

12:15 - 12:45

Building up a successful CDx partnership with Pharma

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

CLINICAL APPLICATIONS OF BIOMARKERS IN IMMUNOLOGY, NEUROLOGY, AND OTHER DISEASES

Leveraging IO markers for companion diagnostics development

14:15 - 14:45

Innovative Safety Biomarker Applications to Drug Development

14:45 - 15:15

Panel Discussion: Biomarker Revolution: Enhancing Patient Care Across Specialties

Nicole Miller

Nicole Miller, Vice President, Molecular Diagnostics Global Medical Affairs, Ultragenyx

 Julius Goepp

Julius Goepp, Founder, CEO, Scaled Microbiomics

15:15 - 15:45

Closing Remarks from the Chairperson

15:45 - 15:50

End of the conference

15:50 - 15:50

SPEAKERS

Ayat Alsaraby

Ayat Alsaraby

Sr. Manager, Clinical Biomarker, Repare Therapeutics

TBA Senior Representative,  AG Pharma

TBA Senior Representative, AG Pharma

TBA Senior Representative, AG Pharma,

TBA Senior Representative,  Predicine

TBA Senior Representative, Predicine

TBA Senior Representative, Predicine,

TBA Senior Representative,  BD Biosciences

TBA Senior Representative, BD Biosciences

TBA Senior Representative, BD Biosciences,

Jiangwei Zhang

Jiangwei Zhang

Senior Principal Scientist, Bristol Myers Squibb

Ranjan Perera

Ranjan Perera

Associate Professor, Johns Hopkins University

Carl Saab

Carl Saab

Professor, Innovation Lead Digital Health, Cleveland Clinic

Nicole Miller

Nicole Miller

Vice President, Molecular Diagnostics Global Medical Affairs, Ultragenyx

Pablo Lapuerta

Pablo Lapuerta

Chief Executive Officer, 4M Therapeutics Inc.

 Julius Goepp

Julius Goepp

Founder, CEO, Scaled Microbiomics

Matteo D’Antonio

Matteo D’Antonio

Assistant Professor, University of California, San Diego

Charles Joel Rosser

Charles Joel Rosser

Medical Director, Cedars-Sinai

Collin

Collin

Scientist, EpigenDx

ENQUIRE NOW

SPONSORS

Predicine
Precision Antibody
EpigenDx
BD Biosciences, USA
Q2 Solutions

LOCATION

Venue

Double Tree by Hilton, San Diego - Mission Valley

PAST EVENT GALLERY